RxDoctor Payments Data

Patrick Harding, MD

Neurology · Williamsburg, VANPI 1467424556

Payments from drug & device makers

$23,115in general payments, 2019–2025

Across 250 payments — averaging $92.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$12K
  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • Inspire Medical Systems, Inc.$2K
  • Jazz Pharmaceuticals Inc.$604
  • Novartis$471
  • Supernus Pharmaceuticals, Inc.$380
  • plus $3K from 37 others

What the payments were for

  • Speaking & faculty fees$14,79464%
  • Travel & lodging$1,5187%
  • Food & beverage$6,70329%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,115 in reported general payments places this provider in the 75th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$106,355
Medicare patients
889
Services billed
1,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b15$143,947
RebifInterferon Beta-1a/Albumin13$133,975
Nurtec OdtRimegepant Sulfate48$76,767
Sumatriptan Succinate40$7,118
Lacosamide29$5,115
Memantine Hcl120$3,063
Lamotrigine ErLamotrigine12$3,033
Carbidopa-LevodopaCarbidopa/Levodopa72$2,667
Gabapentin173$2,201
Levetiracetam104$2,167
Modafinil18$2,081
Carbamazepine16$2,056
Divalproex Sodium20$1,819
Oxcarbazepine20$1,447
Ropinirole Hcl41$1,244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$132$133,97513 claims
Lilly USA, LLCOlanzapine$24$53212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 474 neurology providers in Virginia.

Other neurology in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →